AxoGen, Inc. (AXGN) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

AXGN — Fair Value Analysis

AxoGen, Inc.

Current: $49.15Overvalued

Fair Value Range

Bear Case (25th pct.)

$0.59

-98.8% vs price

Base Case (Median)

$1.14

-97.7% vs price

Bull Case (75th pct.)

$1.14

-97.7% vs price

$0.59$1.14$1.14

◇ = Current price | |Bear |Base | Bull

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$1.14	-97.7%	High (40%)
EV/EBITDA	$0.04	-99.9%	Medium (20%)
EV/FCF	$1.14	-97.7%	Medium (20%)

Interpretation

Based on 3 out of 8 methods, AXGN appears overvalued at the current price of $49.15. The base case fair value of $1.14 implies 97.7% downside.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.